Screen · Berkshire Criteria

Buffett Quality Screen

Buffett's "wonderful business" criteria, quantified into six dimensions: earnings record (20), ROE quality (25 — Fortune's double standard), low leverage (15), pricing power (15), business stability (15) and capital efficiency (10), for a 0–100 total. The entry gate is the first of Berkshire's acquisition criteria — at least $50M average pre-tax earnings over the last three fiscal years (banks and insurers excluded, as leverage is their business model; investment trusts and closed-end funds excluded, as they are portfolios rather than operating companies). Recomputed periodically from each company's last ten fiscal years; cross-listings merged by canonical ticker. Hover the score for the six-dimension breakdown; companies we cover link to their report. score tier "보통", market "Hong Kong", Has report 필터 적용: 5 match(필터 지우기).

# 종목 Mkt Cap Score Baillie 10Y ROE Profit Streak Net Debt/Eq Gross Margin 리포트 FY
1 Laopu Gold Co Ltd 6181 · 홍콩 $7.2B
63/100 보통
48/100 24.4%low 10.9% 6 yr 0.4× 44% Laopu Gold: A Zen Horizon Framework Deep Dive2026년 6월 7일 · Watch FY2025
2 Contemporary Amperex Technology Co., Limite 3750 · 홍콩 $380B
62/100 보통
59/100 16.7%low 8.7% 10 yr+ Net cash 29% CATL: Zen Horizon Framework 심층 분석2026년 6월 4일 · 신중 매수 FY2025
3 WuXi AppTec Co Ltd H 2359 · 홍콩 $61B
62/100 보통
51/100 15.9%low 9.1% 10 yr+ Net cash 40% WuXi AppTec Co., Ltd.: Chemistry Resets the Earnings Base, the U.S. Question Stays Open, and HK$199.10 Leaves No Conservative Discount2026년 8월 12일 · Hold FY2025
4 Xiaomi Corp 1810 · 홍콩 $95B
56/100 보통
48/100 12.8%low 1.7% 8 yr Net cash 16% Xiaomi Group Long-Term Owner-Oriented Research2026년 5월 17일 · Watch FY2025
5 WuXi Biologics 2269 · 홍콩 $20B
56/100 보통
52/100 13.2%low 6.3% 10 yr+ Net cash 43% WuXi Biologics Deep Dive: A Biologics CRDMO Where Manufacturing Delivery Runs Ahead While Valuation Is Held Back by a Geopolitical Discount2026년 6월 12일 · Hold FY2025

Data and methodology: the six dimensions quantify Berkshire's published acquisition criteria and Buffett's shareholder letters (1981/1987/1991/2007 among others). Qualitative tests in the originals (e.g. "simple, understandable business", "management in place") are out of scope, and price ("available at a fair price") is covered by each report's valuation range instead. Financials come from company annual reports (via EODHD); ratios are computed in reporting currency, the USD gate via static FX. "‡" marks companies whose equity is persistently negative or tiny (ROE falls back to ROCE); "†" marks missing gross profit (operating margin used). Investment trusts and closed-end funds are excluded on two tests — name and financial shape (operating margins beyond what an operating company can achieve); REITs and operating asset managers are unaffected. This is a quantitative first pass, not investment advice. When citing this data, please credit Zen Horizon (zh.app). See our methodology for the scoring process.